proTARE: Prospective observational study on indication, planning, technical implementation, and outcome of transarterial radioembolization (TARE) in malignant liver tumors

proTARE: Prospective observational study on indication, planning, technical implementation, and outcome of transarterial radioembolization (TARE) in malignant liver tumors - proTARE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033168

Enrollment

200

Registered

2023-12-21

Start date

2023-12-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0 C78.7 C22.1

Interventions

Group 1: - Indication for TARE established in a certified interdisciplinary tumorboard (TB)

- TARE evaluation and/or TARE therapy carried out

- Follow-up period of 24 months from the TB (6 months if only TARE evaluation) for assessing treatment success and interactions with other therapies.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients for whom the indication for TARE was established in an interdisciplinary tumor board

Exclusion criteria

Exclusion criteria: Age less than 18 years

Design outcomes

Primary

Measure	Time frame
hepatic progression free survival	—

Secondary

Measure	Time frame
progression free survival, overall survival, complication rate	—

Countries

Germany

Contacts

Public ContactChristian Kühnel

Klinik für Nuklearmedizin, Universitätsklinikum Jena

christian.kuehnel@med.uni-jena.de+49 3641 9329801

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026